Last reviewed · How we verify
LP-108
At a glance
| Generic name | LP-108 |
|---|---|
| Sponsor | Guangzhou Lupeng Pharmaceutical Company LTD. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML (PHASE1)
- A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML (PHASE1)
- A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LP-108 CI brief — competitive landscape report
- LP-108 updates RSS · CI watch RSS
- Guangzhou Lupeng Pharmaceutical Company LTD. portfolio CI